Cargando…
Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database
(1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857854/ https://www.ncbi.nlm.nih.gov/pubmed/36661721 http://dx.doi.org/10.3390/curroncol30010072 |
_version_ | 1784873952460406784 |
---|---|
author | Yu, Qiao Li, Zhigui Liu, Yuqing Luo, Yichen Fan, Jingya Xie, Peijun Cao, Xiaoman Chen, Xingyu Wang, Xiaodong |
author_facet | Yu, Qiao Li, Zhigui Liu, Yuqing Luo, Yichen Fan, Jingya Xie, Peijun Cao, Xiaoman Chen, Xingyu Wang, Xiaodong |
author_sort | Yu, Qiao |
collection | PubMed |
description | (1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2) Methods: A total of 355 qualified colorectal cancer (CRC) patients from January 2010 to December 2020 at West China Hospital of Sichuan University were selected to receive capecitabine monotherapy for 6–9 months and >12 months. The main endpoints were overall survival (OS) and disease-free survival (DFS). (3) Results: Among stage III patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 80.7%% and 66.8%, respectively, and the 5-year OS rates were 94.7%% and 88.8%, respectively. Among high-risk stage II patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 81.5% and 78.6%, respectively, and the 5-year OS rates were 93.1% and 84.2%, respectively. (4) Conclusions: Twelve months of chemotherapy demonstrated superior OS and DFS to that of six months in the stage III group but showed no difference in the high-risk stage II group. The better OS and DFS observed in the 12-month treatment period could be of value in selected cases. |
format | Online Article Text |
id | pubmed-9857854 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98578542023-01-21 Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database Yu, Qiao Li, Zhigui Liu, Yuqing Luo, Yichen Fan, Jingya Xie, Peijun Cao, Xiaoman Chen, Xingyu Wang, Xiaodong Curr Oncol Article (1) Background: The duration of adjuvant chemotherapy recommended by the NCCN guidelines is 6 months. However, patients are not compliant with intravenous chemotherapy for many reasons; therefore, one approach is to obtain a survival benefit by prolonging the duration of capecitabine monotherapy. (2) Methods: A total of 355 qualified colorectal cancer (CRC) patients from January 2010 to December 2020 at West China Hospital of Sichuan University were selected to receive capecitabine monotherapy for 6–9 months and >12 months. The main endpoints were overall survival (OS) and disease-free survival (DFS). (3) Results: Among stage III patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 80.7%% and 66.8%, respectively, and the 5-year OS rates were 94.7%% and 88.8%, respectively. Among high-risk stage II patients, in the >12 months (12M) and 6–9 months (6M) groups, the 5-year DFS rates were 81.5% and 78.6%, respectively, and the 5-year OS rates were 93.1% and 84.2%, respectively. (4) Conclusions: Twelve months of chemotherapy demonstrated superior OS and DFS to that of six months in the stage III group but showed no difference in the high-risk stage II group. The better OS and DFS observed in the 12-month treatment period could be of value in selected cases. MDPI 2023-01-10 /pmc/articles/PMC9857854/ /pubmed/36661721 http://dx.doi.org/10.3390/curroncol30010072 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yu, Qiao Li, Zhigui Liu, Yuqing Luo, Yichen Fan, Jingya Xie, Peijun Cao, Xiaoman Chen, Xingyu Wang, Xiaodong Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
title | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
title_full | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
title_fullStr | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
title_full_unstemmed | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
title_short | Effect of Different Durations of Adjuvant Capecitabine Monotherapy on the Outcome of High-Risk Stage II and Stage III Colorectal Cancer: A Retrospective Study Based on a CRC Database |
title_sort | effect of different durations of adjuvant capecitabine monotherapy on the outcome of high-risk stage ii and stage iii colorectal cancer: a retrospective study based on a crc database |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857854/ https://www.ncbi.nlm.nih.gov/pubmed/36661721 http://dx.doi.org/10.3390/curroncol30010072 |
work_keys_str_mv | AT yuqiao effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT lizhigui effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT liuyuqing effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT luoyichen effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT fanjingya effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT xiepeijun effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT caoxiaoman effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT chenxingyu effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase AT wangxiaodong effectofdifferentdurationsofadjuvantcapecitabinemonotherapyontheoutcomeofhighriskstageiiandstageiiicolorectalcanceraretrospectivestudybasedonacrcdatabase |